Drug Companies Pursuing Alzheimer Treatments See Shares Rise Wednesday
September 28 2022 - 1:45PM
Dow Jones News
By Stephen Nakrosis
The shares of several companies pursuing treatments for
Alzheimer's Disease got a boost on Wednesday, after Eisai Co. Ltd.
and Biogen Inc. said a study of their lecanemab showed highly
statistically significant reduction of clinical decline in early
Alzheimer's Disease.
Eisai said it plans to discuss the data with regulatory
authorities in the U.S., Japan and Europe. The company also said it
aims to file for traditional approval in the U.S. and for marketing
authorization applications in Japan and Europe by March 31,
2023.
Shares of Acumen Pharmaceuticals Inc. had nearly doubled at
midday, trading about 97% higher, at $9.26 a share. Volume at the
time topped 45.2 million shares, above the stock's 65-day average
volume of just over 61,000 shares.
Shares of Prothena Corp. PLC were trading around 72% higher, at
$53.14 a share. Volume at the time was over 7.1 million shares. The
stock's 65-day average volume is 373,989 shares.
Denali Therapeutics Inc. shares were up nearly 21% higher, at
$33.01 a share. Volume at the time topped 1.3 million shares, above
the stock's 65-day average volume of 617,185 shares.
Shares of Biogen were up more than 37%, at $270.97 a share.
Volume topped 11.7 million shares, above the 65-day average volume
of 907,162 shares.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 28, 2022 13:30 ET (17:30 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From May 2024 to Jun 2024
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jun 2023 to Jun 2024
